Table 4.
Cost drivers, mean cost, and percent contribution to total costs of Option B+ services per health facility.
| Cost drivers | Mean year 1 costs∗ | Mean year 2 costs∗ | Total 2-year cost | Mean cost per mother-babypair | Mean percent contribution (range) % |
|---|---|---|---|---|---|
| Personnel | |||||
| Facility personnel | 2,711.8 | 2,774.1 | 5,485.9 | 36.5 | 8.2 (7.7–11.6) |
| Medications | |||||
| ART (TDF+3TC+EFV) | 20,589.4 | 21,062.6 | 41,652.0 | 276.8 | 62.6 (56.0–65.5) |
| Nevirapine syrup | 195.4 | 199.9 | 395.3 | 2.6 | 0.6 (0.5–0.6) |
| Cotrimoxazole | 1,820.6 | 1,862.5 | 3,683.1 | 24.5 | 5.5 (49–5.8) |
| Laboratory testing | |||||
| HIV enzyme immunoassay (EIA) tests | 402.2 | 411.5 | 813.7 | 5.4 | 1.2 (1.1–1.3) |
| CD4 counts | 1,204.0 | 1,231.7 | 2,435.7 | 16.2 | 3.7 (3.3–3.8) |
| 1st HIV DNA PCR | 1,710.0 | 1,749.3 | 3,459.3 | 23.0 | 5.2 (2.2–6.7) |
| 2nd HIV DNA PCR | — | 337.5 | 337.5 | 2.2 | 0.5 (NA) |
| DBS sample transportation for HIV DNA PCR testing∗∗ | 593.8 | 607.4 | 1,201.2 | 8.0 | 1.8 (1.6–1.9) |
| Above-site coordination, supervision, and training | |||||
| MOH | 104.4 | 106.8 | 211.2 | 1.4 | 0.3 (0.2–0.3) |
| TASO | 1,155.4 | 1,181.9 | 2,337.3 | 15.5 | 3.5 (3.2–3.9) |
| Option B+ training | 135.3 | 138.4 | 273.8 | 1.8 | 0.4 (0.2–0.4) |
| Facility-level monitoring and quality improvement | 1,973.6 | 2,019.0 | 3,992.5 | 26.5 | 6.0 (3.2–12.3) |
| Overheads | 115.7 | 118.4 | 234.2 | 1.6 | 0.4 (0.2–0.7) |
| Grand total | 32,711.7 | 33,801.0 | 66,512.7 | 441.9 | 100.0% |
All costs are in 2014 USD. ∗Cost incurred in the second year (2015) were inflated by the ratio of 2015 and 2014 USA GDP implicit price deflator. ∗∗SUSTAIN supported transportation of DBS samples.